Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced primarily by intestinal L-cells in response to food intake
For patients with BMIs that started above 35, significant metabolic syndrome, or a history of yo-yo dieting, maintenance dosing often produces the best long-term outcomes
When these nutrients make contact with L-cells, they trigger a cascade of cellular signals that result in GLP-1 synthesis and secretion
This enables a semi-permanent, just-eaten sensation of fullness that consequently leads to decreased food intake and, ultimately, weight loss
It should be considered a Part D insurance
Therefore, the development of novel, safer, and more effective therapies for the clinical management of women with PCOS and their metabolic complications remains an unmet medical need